A new approach to prostate cancer screening-Reference-Cited by-同舟云学术

A new approach to prostate cancer screening

Published:2023-08-03 Issue:3 Volume:4 Page:207-211
ISSN:2628-491X
Container-title:Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
language:en
Short-container-title:

Author:

Filella Xavier¹,González Álvaro²,Augé Josep Maria¹^ORCID,Barco Antonio³,Carbonell Rosa⁴,Gaspar María Jesús⁵,Martínez-Peinado Antonio⁶,Barrios Clara Pérez⁷,Sánchez-Carbayo Marta⁸,Santotoribio José Diego⁹,Trapé Jaume¹⁰

Affiliation:

1. Service of Biochemistry and Molecular Genetics, CDB , Hospital Clínic de Barcelona, IDIBAPS , Barcelona , Spain

2. Service of Biochemistry , Clínica Universidad de Navarra , Pamplona , Spain

3. Service of Clinical Biochemistry , Miguel Servet University Hospital , Zaragoza , Spain

4. Laboratory of Biochemistry , San Juan University Hospital , San Juan , Alicante , Spain

5. Service of Clinical Analysis , Hospital Universitario Príncipe de Asturias , Alcalá de Henares , Madrid , Spain

6. Clinical Analsysis Management Unit, Section of Molecular Genetics , Reina Sofía University Hospital , Córdoba , Spain

7. Laboratory , Puerta de Hierro University Hospital , Majadahonda , Madrid , Spain

8. Department of Health Sciences , Universidad Pontificia , Salamanca , Spain

9. Laboratory , Hospital Universitario Virgen del Rocio , Seville , Spain

10. Laboratory , Althaia Xarxa Assitencial Universitària , Manresa , Spain

Abstract

Abstract Prostate cancer screening based on prostate-specific antigen (PSA) testing has been a matter of controversy. Although screening for prostate cancer was effective in reducing mortality, it resulted in overdiagnosis, which translated into unnecessary treatments and numerous adverse effects. As a result, recommendations from scientific societies became increasingly restrictive. In the recent years, new approaches to prostate cancer screening have been proposed. These new approaches are aimed at solving the controversy between widespread screening vs. no screening, and reconsidering PSA testing as a screening tool with a good benefit/risk balance. In this context, the European Association of Urology submitted a proposal to the European Commission for prostate cancer screening to be performed as a function of baseline PSA concentrations. The European Commission recently recommended the implementation of organized prostate cancer screening programs for men aged ≤70 years based on PSA values in combination with follow-up magnetic resonance imaging.

Publisher

Walter de Gruyter GmbH

Subject

Medical Laboratory Technology,Education,Medicine (miscellaneous)

Link

https://www.degruyter.com/document/doi/10.1515/almed-2023-0082/pdf

Reference35 articles.

1. Sociedad Española de Oncología, Médica. Las cifras del cáncer en España 2022. SEOM. https://seom.org/publicaciones/el-cancer-en-espanyacom [Acceso 20 abril 2023].

2. Schroder, FH, Hugosson, J, Roobol, MJ, Tammela, TL, Zappa, M, Nelen, V, et al.. Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027–35. https://doi.org/10.1016/s0140-6736(14)60525-0.

3. Hugosson, J, Roobol, MJ, Månsson, M, Tammela, TLJ, Zappa, M, Nelen, V, et al.. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol 2019;76:43–51. https://doi.org/10.1016/j.eururo.2019.02.009.

4. Andriole, GL, Crawford, ED, Grubb, RL3rd, Buys, SS, Chia, D, Church, TR, et al.. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125–32. https://doi.org/10.1093/jnci/djr500.

5. Pinsky, PF, Miller, E, Prorok, P, Grubb, R, Crawford, ED, Andriole, G. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int 2019;123:854–60. https://doi.org/10.1111/bju.14580.